Artesunate not checked
Frantz Viral Therapeutics, LLC
FollowEvery change as it happens, and a Monday email
Trials
4 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Four 5-day cycles of artesunate ointment given at weeks 0, 2, 4, 6”In the company’s words, NCT06206564 on ClinicalTrials.gov
- Tested for
- HPV Infection (3 trials), Pre-Cancerous Dysplasia (2 trials), HPV Disease (2 trials), CIN 2/3, Cervical Dysplasia, HPV Related Disease, Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition and 16 more
- Main trialPhase 2
- “This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).”In the company’s words, NCT04098744 on ClinicalTrials.gov
- Other names
- Artesunic acid · Artemisinin · DHA
Other drugs for HPV Infection
- VP-102Verrica Pharmaceuticals Inc. · Phase 3
- CervavacSerum Institute of India Pvt. Ltd. · Phase 3
- V503Merck & Co. · Phase 3
- 9-valent Human Papillomavirus Recombinant VaccineShanghai Bovax Biotechnology Co., Ltd. · Phase 3
- GardasilMerck & Co. · Phase 3
- 11-valent recombinant human papilloma virus vaccineNational Vaccine and Serum Institute, China · Phase 3
Coming up3
- 28 DecPhase 2 trial completes · ClinicalTrials.gov
- DecPhase 2 trial completes · ClinicalTrials.gov
- 31 DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Jul 2026 | Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3) | |
| Phase 2Active, not recruiting | 28 Dec 2026 | Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL | |
| Phase 2Recruiting | Dec 2026 | Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3) | |
| Phase 2Recruiting | 31 Dec 2026 | Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026